Background
There are few reports on the prevalence of different types of cardiomyopathy, clinical presentation, severity,
short-term outcomes, and implementation of advanced heart failure treatment. This study aimed to assess
the prevalence, clinical background of different types of cardiomyopathy and to identify the candidate for
advanced treatment in a tertiary care cardiac center with many advantages
Method
A single-center retrospective cohort study included 1069 patients admitted to our center and diagnosed with
cardiomyopathy during 2019 and 2020
Results
Out of 1069 cardiomyopathy patients admitted and diagnosed at our center between 2019 and 2020, 62%
had ischemic cardiomyopathy (ICM), 36% had dilated cardiomyopathy (DCM), and 2% had hypertrophic
cardiomyopathy (HOCM). ICM patients were older, showed a higher prevalence of both male gender and
pilgrims, and they had more frequent cardiovascular risk factors compared to dilated cardiomyopathy group
of patients. However, DCM patients with more severe heart failure symptoms (NYHA class III/IV), much
worse LVEF, were subsequently considered deemed for aggressive diuretic therapy, and further advanced
therapy (Sacubitril-Valsartan and device therapy) compared to ICM patients. ICM patients showed poor inhospital
outcomes compared to DCM group of patients (0.05 and |
